Key Takeaways
- Conneqt Health has submitted an FDA Pre-Submission for its SphygmoCor Cloud platform, seeking 510(k) clearance in the U.S.
- The transition to a cloud-based software system aims to enhance accessibility and integration with various health technologies.
- Potential FDA clearance could open up new commercial pathways, shifting the business model from hardware sales to software licensing and subscriptions.
FDA Submission for SphygmoCor Cloud
Conneqt Health Ltd (ASX:CQT) is advancing its cardiovascular health technology by submitting an FDA Pre-Submission package for its SphygmoCor Cloud, a next-generation Software as a Medical Device (SaMD) platform. This initiative marks a crucial move toward receiving 510(k) clearance in the United States, with an anticipated written response from the FDA by August 2026.
If approved, SphygmoCor Cloud will become CONNEQT’s sixth FDA-cleared product, transitioning from traditional hardware to a cloud-based solution for arterial health analytics. The Pre-Submission was made under the FDA’s Q-Submission program, enabling CONNEQT to gain feedback on regulatory, clinical, technical, and quality aspects before proceeding with the full 510(k) application.
CONNEQT plans a Pre-Submission meeting for late August or early September 2026, aiming for a 510(k) submission in Q2 FY27. Targeted FDA clearance is projected for Q3–Q4 FY27, depending on review timelines and the adequacy of responses to any additional requests.
Transition to Cloud-Based Solutions
SphygmoCor Cloud aims to migrate the company’s validated cardiovascular analytics engine to a cloud-based architecture, allowing broader access without the need for dedicated hardware. The technology, which has been in use since its initial FDA clearance in 2002, is currently employed in hospitals, research institutions, and clinical programs worldwide.
This transition is anticipated to unlock new commercial avenues, such as Biomarker-as-a-Service and integration with third-party devices. The platform will also support API-based integrations with medical-grade peripherals and consumer health technologies. Health systems, insurers, and employer programs could utilize SphygmoCor Cloud for cardiovascular risk assessments, further expanding its applicability.
The strategy reflects a major shift from one-time device sales to a potential model emphasizing software licensing and subscription revenue. CEO Craig Cooper remarked, “This is a significant step forward for CONNEQT, not just the filing, but the opportunity it opens up.” He noted that while devices remain central, SphygmoCor Cloud could allow for independent scaling, tapping into a much larger market.
About CONNEQT Health
CONNEQT Health specializes in medical technology focused on vascular health, offering a range of devices and digital solutions for hypertension and cardiovascular disorders, utilizing its SphygmoCor vascular biomarker technology.
The content above is a summary. For more details, see the source article.
